Systemic levels following PGE1 inhalation in neonatal hypoxemic respiratory failure

Acta Paediatrica, International Journal of Paediatrics

Volumn 95, Issue 9, 2006, Pages 1093-1098

  Sood, Beena Gaind ^a   Glibetic, Maria ^a,b   Aranda, Jacob V ^a   Delaney Black, Virginia ^a   Chen, Xinguang ^a   Shankaran, Seetha ^a  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^b Medical School   (Serbia)

Author keywords

Aerosol; Enzyme immunoassay; Hypoxemic respiratory failure; Prostaglandin E1 alprostadil; Selective pulmonary vasodilator

Indexed keywords

PROSTAGLANDIN E1; OXYGEN; VASODILATOR AGENT;

ARTERIAL OXYGEN TENSION; ARTICLE; BLOOD PRESSURE; BLOOD SAMPLING; BODY TEMPERATURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGENITAL HEART DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERANCE; ENZYME IMMUNOASSAY; HEART RATE; HUMAN; LUNG INSUFFICIENCY; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN; OXYGEN THERAPY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; BLOOD; CONGENITAL HEART MALFORMATION; FEMALE; HYPOXEMIA; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; RESPIRATORY FAILURE;

ADMINISTRATION, INHALATION; ALPROSTADIL; ANOXEMIA; FEMALE; HEART DEFECTS, CONGENITAL; HUMANS; INFANT, NEWBORN; INFUSIONS, INTRAVENOUS; MALE; OXYGEN; RESPIRATORY INSUFFICIENCY; VASODILATOR AGENTS;

EID: 33748636264     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1080/08035250600580511     Document Type: Article

References (25)

1. Ferreira SH, Vane JR. Prostaglandins: Their disappearance from and release into the circulation. Nature 1967;216:868-73.
2. Piper PJ, Vane JR, Wyllie JH. Inactivation of prostaglandins by the lungs. Nature 1970;225:600-4.
3. Awad JA, Soteriou MC, Drougas JG, Stokes KA, Roberts LJ 2nd, Pinson CW. Plasma prostaglandin E1 concentrations and hemodynamics during intravenous infusions of prostaglandin E1 in humans and swine. Transplantation 1996;61:1624-9.
4. Walsh-Sukys MC, Tyson JE, Wright LL, Bauer CR, Korones SB, Stevenson DK, et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics 2000;105:14-20.
5. Drummond WH, Gregory GA, Heymann MA, Phibbs RA. The independent effects of hyperventilation, tolazoline, and dopamine on infants with persistent pulmonary hypertension. J Pediatr 1981;98:603-11.
6. Graves ED, 3rd, Redmond CR, Arensman RM. Persistent pulmonary hypertension in the neonate. Chest 1988;93:638-41.
7. Radermacher P, Santak B, Becker H, Falke KJ. Prostaglandin E1 and nitroglycerin reduce pulmonary capillary pressure but worsen ventilation-perfusion distributions in patients with adult respiratory distress syndrome. Anesthesiology 1989;70:601-6.
8. Walmrath D, Schermuly R, Pilch J, Grimminger F, Seeger W. Effects of inhaled versus intravenous vasodilators in experimental pulmonary hypertension. Eur Respir J 1997;10:1084-92.
9. Meyer J, Theilmeier G, Van Aken H, Bone HG, Busse H, Waurick R, et al. Inhaled prostaglandin E1 for treatment of acute lung injury in severe multiple organ failure. Anesth Analg 1998;86:753-8.
10. Putensen C, Hormann C, Kleinsasser A, Putensen-Himmer G. Cardiopulmonary effects of aerosolized prostaglandin E1 and nitric oxide inhalation in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1998;157:1743-7.
11. Sood BG, Delaney-Black V, Aranda JV, Shankaran S. Aerosolized PGE1: A selective pulmonary vasodilator in neonatal hypoxemic respiratory failure. Results of a phase I/II open label clinical trial. Pediatr Res 2004;56:579-85.
12. 1 enzyme immunoassay kit. In: Catalog No. 900-005. Ann Arbor, MI, USA: Assay Designs, Inc.; 1996.
13. Leonhardt A, Kuhl PG, Schweer H, Wolf D, Seyberth HW. Pharmacologically active levels of PGE1 in neonates with congenital heart disease. Acta Paediatr Scand 1989;78:853-7.
14. Schweer H, Meese CO, Watzer B, Seyberth HW. Determination of prostaglandin E1 and its main plasma metabolites 15-keto-prostaglandin E0 and prostaglandin E0 by gas chromatography/negative ion chemical ionization triple-stage quadruple mass spectrometry. Biol Mass Spectrom 1994;23:165-70.
15. Keirse MJ, Turnbull AC. E prostaglandins in amniotic fluid during late pregnancy and labour. J Obstet Gynaecol Br Commonw 1973;80:970-3.
16. Hammes W, Buchsler U, Kinder P, Bokens H. Simultaneous determination of prostaglandin E1, prostaglandin E0 and 15-keto-prostaglandin E0 in human plasma by gas chromatography/negative-ion chemical-ionization tandem mass spectrometry. J Chromatogr A 1999;847:187-202.
17. Cawello W, Leonhardt A, Schweer H, Seyberth HW, Bonn R, Lomeli AL. Dose proportional pharmacokinetics of alprostadil (prostaglandin E1) in healthy volunteers following intravenous infusion. Br J Clin Pharmacol 1995;40:273-6.
18. Schweer H, Cawello W, Seyberth HW. Gas chromatography/ negative ion chemical ionization triple quadruple mass spectrometric determination and pharmacokinetics of 11 alpha-hydroxy-9,15-dioxo-2,3,4,5,20-pentanor-19- carboxyprostan oic acid in plasma. Prostaglandins Leukot Essent Fatty Acids 1994;51:401-5.
19. Cawello W, Schweer H, Muller R, Bonn R, Seyberth HW. Metabolism and pharmacokinetics of prostaglandin E1 administered by intravenous infusion in human subjects. Eur J Clin Pharmacol 1994;46:275-7.
20. Kunimoto F, Arai K, Isa Y, Koyano T, Kadoi Y, Saito S, et al. A comparative study of the vasodilator effects of prostaglandin E1 in patients with pulmonary hypertension after mitral valve replacement and with adult respiratory distress syndrome. Anesth Analg 1997;85:507-13.
21. Cox JW, Andreadis NA, Bone RC, Maunder RJ, Pullen RH, Ursprung JJ, et al. Pulmonary extraction and pharmacokinetics of prostaglandin E1 during continuous intravenous infusion in patients with adult respiratory distress syndrome. Am Rev Respir Dis 1988;137:5-12.
22. Nagata I, Seki K, Uesato T, Sunaga H, Furuya K, Makimura N, et al. Changes in plasma oxytocin, prostaglandin E1, and 13,14-dihydro-15-keto- prostaglandin F2 alpha during labor induced by prostaglandin E2 or F2 alpha and spontaneous labor. Nippon Sanka Fujinka Gakkai Zasshi 1987;39:1627-33.
23. Shimizu T, Yamashiro Y, Yabuta K. Prostaglandin E1, E2, and F2 alpha in human milk and plasma. Biol Neonate 1992;61:222-5.
24. Leonhardt A, Schweer H, Wolf D, Seyberth HW. Formation of biologically active 13,14-dihydro-prostaglandin E1 during intravenous infusion of prostaglandin E1 in newborns with ductus arteriosus-dependent congenital heart disease. Br J Clin Pharmacol 1992;33:323-5.
25. Borok Z, Gillissen A, Buhl R, Hoyt RF, Hubbard RC, Ozaki T, et al. Augmentation of functional prostaglandin E levels on the respiratory epithelial surface by aerosol administration of prostaglandin E. Am Rev Respir Dis 1991;144:1080-4.